Medtech Q1 Earnings: What the Major Strategics Are Telling Us

With Q2 already underway, the latest medtech Q1 earnings reports offer an early read on where major strategics are gaining momentum, where pressure is building, and what strategic priorities are becoming clearer.

This quarter’s results point to a consistent theme: focused portfolios are outperforming broader platforms. Companies concentrated in clearly defined growth markets, particularly cardiovascular/structural heart, are delivering stronger execution. More diversified players remain highly competitive, but they are managing a wider mix of operational, integration, and macroeconomic challenges.

A closer look at the numbers makes that trend difficult to ignore.

Focused Players Continue to Separate Themselves

Abbott delivered $5.5 billion in Q1 Medical Devices revenue, representing 8.5% organic growth and 13.2% reported growth year over year. Electrophysiology, Rhythm Management, and Heart Failure each posted double-digit gains, while the U.S. launch of Volt supported EP performance. Continuous glucose monitors contributed $2 billion of the quarterly total.

Still, softer U.S. prescription demand in diabetes care, delayed international tenders, and investor concerns around slowing organic momentum weighed on sentiment. The Exact Sciences acquisition also introduces integration complexity.

Boston Scientific generated $5.2 billion in Q1 revenue, up 9.4% organically and 11.6% reported. Cardiovascular remained the growth engine, climbing 13.5%. However, management reduced guidance from 10%–11% growth to 6.5%–8%, reflecting pressure across electrophysiology, WATCHMAN, and urology.

The EP story is especially notable. After benefiting from an early pulsed-field ablation advantage, Boston Scientific is now facing intensifying competition. Meanwhile, acquisition integration remains uneven, with Axonics experiencing commercial disruption while Valencia Technologies may provide support to urology over time.

Edwards Lifesciences posted one of the strongest quarters among peers, reaching $1.7 billion in revenue with 16.7% reported growth. Performance exceeded expectations across segments, prompting management to raise full-year guidance to 9%–11%.

TAVR growth of 14.4% stands out, given the maturity of that segment. Strong clinical evidence supporting earlier intervention continues to expand the addressable market, and Edwards appears well-positioned to apply that strategy in adjacent structural heart categories.

Medtech Q1 Earnings Reveal The Value Of Portfolio Discipline

Intuitive continues to execute at an exceptionally high level. Q1 revenue climbed 23% year over year to $2.8 billion, exceeding estimates by nearly 6%. da Vinci procedure volumes reached approximately 874,000 cases, while Ion volumes climbed to roughly 43,000 procedures. da Vinci 5 placements nearly doubled, reaching 232 for the quarter.

Challenges remain in China and Japan, where domestic competition, pricing pressure, and low tender activity are weighing on performance. U.S. bariatric procedures also declined about 10%, reflecting the continued impact of GLP-1 adoption.

Even so, management raised procedure growth expectations for the year, an important signal for future recurring revenue.

Insulet reported 33.9% revenue growth, reaching $762 million. International Omnipod sales jumped nearly 60%, and guidance was raised again.

Yet despite strong operating performance, shares fell sharply following results. An unusual $87 million expense, a voluntary recall, concerns about competitive dynamics, and expectations that had climbed even higher all contributed to investor disappointment.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/medtech-q1-earnings-what-the-major-strategics-are-telling-us

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more